Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection-Reference-Cited by-同舟云学术

Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection

Published:2016-09 Issue:9 Volume:36 Page:e148-e153
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Bunnell Kristen L.¹,Vibhakar Sonia²,Glowacki Robert C.¹³,Gallagher Maureen A.²,Osei Albert M.³,Huhn Gregory²³

Affiliation:

1. College of Pharmacy; University of Illinois at Chicago; Chicago Illinois

2. Ruth M. Rothstein CORE Center; Cook Country Health and Hospitals System; Chicago Illinois

3. John H. Stroger Jr. Hospital; Cook County Health and Hospitals System; Chicago Illinois

Publisher

Wiley

Subject

Pharmacology (medical)

Reference34 articles.

1. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: interferon free is now;Florian;Clin Pharmacol Ther,2015

2. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus;AASLD/IDSA HCV Guidance Panel;Hepatology,2015

3. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: considerations for antiretroviral use in patients with coinfections 2015

4. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1;Naggie;N Engl J Med,2015

5. Gilead Sciences, Inc Harvoni (ledipasvir and sofosbuvir) package insert Foster City, CA 2015

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety considerations in the management of hepatitis C and HIV co-infection;Expert Opinion on Drug Safety;2023-04-27

2. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

3. KASL clinical practice guidelines for management of chronic hepatitis B;Clinical and Molecular Hepatology;2022-04-01

4. Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine;Journal of Clinical and Experimental Hepatology;2021-08

5. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus‐coinfected patients receiving sofosbuvir‐based direct‐acting antivirals and antiretroviral therapy;Journal of Viral Hepatitis;2021-04-03